Recently, Meiyin Intelligent Technology Co., Ltd., a Hangzhou-based medical AI company, announced the completion of a multi-million-dollar seed round financing. The funds will primarily be used for the R&D and commercialization of its core products. This round was led by Zhuoyuan Asia and other institutions, with follow-on investment from the Xihu Government Direct Investment Fund.
Meiyin Intelligent focuses on leveraging artificial intelligence to predict disease risks and promote health management. Its core product is based on its self-developed DP-LLM large model, capable of processing multi-modal medical data and accurately quantifying an individual's future disease risks, covering hundreds of diseases and tens of thousands of risk factors. Founder and CEO Guo Xiaoyu stated that compared to traditional medical AI tools, modern generative large models possess stronger sequential prediction capabilities, enabling them to analyze an individual's health data and predict their future health status and disease progression.
Image Source Note: Image generated by AI, licensed through Midjourney.
Previously, due to a lack of high-quality data and accurate risk assessment models, many insurance product terms were often very strict, especially with many limitations for individuals with pre-existing conditions. However, with Meiyin Intelligent's model, insurance product design can be more refined, offering different levels of coverage to different groups. Individuals with early disease risks can expect better insurance coverage.
To improve model accuracy, Meiyin Intelligent has integrated a large amount of medical literature and clinical data, conducting in-depth research on disease risk factors and their correlations. Furthermore, the company is building a knowledge graph to reduce the "hallucination" problem in the practical application of AI models, ensuring the reliability of the output results.
Guo Xiaoyu pointed out that relying solely on hospitals and doctors to promote medical AI products is limited; the true market potential lies in directly serving individuals. Therefore, Meiyin Intelligent has chosen to collaborate with commercial insurers, jointly developing health insurance products with government departments and large insurance companies. They are expanding their market through technology service fees and subscription models while also developing more health management products.
Regarding the team background, founder Guo Xiaoyu has over ten years of experience in the medical AI industry and previously held a position in a publicly listed company, responsible for the rapid growth of its health insurance technology sector. His team members also have strong backgrounds, possessing extensive technical and commercialization experience, ensuring Meiyin Intelligent's competitiveness in future development.
